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Abstract
Background: DNA methyltransferases (DNMTs) are epigenetic enzymes involved in embryonic development, cell
differentiation, epithelial to mesenchymal transition, and control of gene expression, whose overexpression or enhanced
catalytic activity has been widely reported in cancer initiation and progression. To date, two DNMT inhibitors (DNMTi),
5-azacytidine (5-AZA) and 5-aza-2′-deoxycytidine (DAC), are approved for the treatment of myelodysplastic syndromes
and acute myeloid leukemia. Nevertheless, they are chemically instable and quite toxic for healthy cells; thus, the
discovery of novel DNMTi is urgent.
Results: Here, we report the identification of a new quinoline-based molecule, MC3353, as a non-nucleoside inhibitor and
downregulator of DNMT. This compound was able, in promoter demethylating assays, to induce enhanced green
fluorescence protein (EGFP) gene expression in HCT116 cells and transcription in a cytomegalovirus (CMV) promoter-
driven luciferase reporter system in KG-1 cells. Moreover, MC3353 displayed a strong antiproliferative activity when tested
on HCT116 colon cancer cells after 48 h of treatment at 0.5 μM. At higher doses, this compound provided a cytotoxic
effect in double DNMT knockout HCT116 cells. MC3353 was also screened on a different panel of cancer cells (KG-1 and
U-937 acute myeloid leukemia, RAJI Burkitt’s lymphoma, PC-3 prostate cancer, and MDA-MB-231 breast cancer), where it
arrested cell proliferation and reduced viability after 48 h of treatment with IC50 values ranging from 0.3 to 0.9 μM.
Compared to healthy cell models, MC3353 induced apoptosis (e.g., U-937 and KG-1 cells) or necrosis (e.g., RAJI cells) at
lower concentrations. Importantly, together with the main DNMT3A enzyme inhibition, MC3353 was also able to
downregulate the DNMT3A protein level in selected HCT116 and PC-3 cell lines. Additionally, this compound provided
impairment of the epithelial-to-mesenchymal transition (EMT) by inducing E-cadherin while reducing matrix
metalloproteinase (MMP2) mRNA and protein levels in PC-3 and HCT116 cells. Last, tested on a panel of primary
osteosarcoma cell lines, MC3353 markedly inhibited cell growth with low single-digit micromolar IC50 ranging from 1.1 to
2.4 μM. Interestingly, in Saos-2 osteosarcoma cells, MC3353 induced both expression of genes and mineralized the matrix
as evidence of osteosarcoma to osteoblast differentiation.
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Conclusions: The present work describes MC3353 as a novel DNMTi displaying a stronger in cell demethylating ability
than both 5-AZA and DAC, providing re-activation of the silenced ubiquitin C-terminal hydrolase L1 (UCHL1) gene.
MC3353 displayed dose- and time-dependent antiproliferative activity in several cancer cell types, inducing cell death and
affecting EMT through E-cadherin and MMP2 modulation. In addition, this compound proved efficacy even in primary
osteosarcoma cell models, through the modulation of genes involved in osteoblast differentiation.
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Introduction
Epigenetics studies the changes in gene expression not
caused by alterations in the DNA base sequence and lead-
ing to a heritable and stable phenotype [1–3]. The epigen-
etic machinery is regulated by chromatin modifications
involving histone and/or DNA modifications and nucleo-
some positioning and by non-coding RNAs [4]. In
humans, a main epigenetic modification is DNA methyla-
tion, described as a stable epigenetic mark occurring at
the C-5 position of cytosine residues in DNA regions
called CpG islands. The reaction is catalyzed by DNA
methyltransferases (DNMTs, namely DNMT1, DNMT3A,
and DNMT3B), which use hemimethylated or unmethy-
lated DNA as the substrate and S-adenosyl-L-methionine
(AdoMet) as the methyl donor co-substrate [5, 6].
DNA methylation is essential for crucial processes such
as embryonic development or differentiation [5, 7]. In can-
cer, aberrant DNA methylation patterns have been exten-
sively described, leading to CpG island hypermethylation
together with global hypomethylation and subsequent in-
activation of tumor suppressor genes (TSGs) and genomic
instability [5, 7–9]. Genetic or pharmacological DNMT1
inhibition has been reported to be sufficient to lead to
TSG re-expression and cell growth arrest in a variety of
cancer cells in vitro, such as lung, esophagus, stomach,
breast, cervix, brain, head, and neck cancer cells [10–14].
DNMT inhibitors (DNMTi) are currently classified into
nucleoside analogs including 5-azacytidine (5-AZA) and
5-aza-2′-deoxycytidine (DAC; decitabine), approved in
2004 and 2006, respectively, by US FDA for the treatment
of myelodysplasia and other hematological malignancies,
and non-nucleoside analogs, obtained by natural sources,
repositioning of old drugs (for example, hydralazine and
procainamide [13–15]) or by identification of new chem-
ical entities (RG-108 [16] and its benzoylproline analog
[17], nitrophenyl-chromenones and -chromanones [18],
SGI-1027 [19] and its regioisomer MC3343 [20–22], qui-
nazoline derivatives such as compound 14 [23], and com-
pound 68 [24]) (Fig. 1).
The two approved nucleoside DNMTi suffer from
poor bioavailability, chemical instability, and adverse side
effects, while non-nucleoside DNMTi are often not spe-
cific, scarcely potent, and with an unknown mechanism
of action [5, 12–14]. Among the latter, SGI-1027 is the
most reliable compound, since it shows a significant ef-
fect against DNMT1 and DNMT3A at a low micromolar
level and displays arrest of proliferation and TSG reacti-
vation in cancer cells [19]. Previously, we performed
chemical manipulations on the SGI-1027 structure by
preparing all of its regioisomers as well as some trun-
cated and symmetric bis-quinoline and bis-pyrimidine
analogs [20]. From this study, the N-(3-(2-amino-6--
methylpyrimidin-4-ylamino)phenyl)-3-(quinolin-4-ylami-
no)benzamide MC3343 (Fig. 1) emerged as a novel hit
compound showing higher potency and selectivity than
SGI-1027 with respect to other AdoMet-dependent his-
tone/protein methyltransferases [20] and a different
mechanism of action [21]. In a panel of cancer cells,
MC3343 showed similar antiproliferative activities as
SGI-1027 but reduced toxicity [20], even displaying in-
hibition of proliferation and induction of cytodifferentia-
tion in medulloblastoma cancer stem cells [20].
Furthermore, MC3343 also impaired tumor proliferation
of osteosarcoma cells by blocking the cell cycle in G1 or
G2/M phases and induced osteoblastic differentiation
through the specific re-expression of genes regulating
this physiological process. MC3343 displayed these bio-
logical effects even in vivo against a patient-derived
xenograft [22].
Prompted by these results, we designed a novel analog of
SGI-1027, MC3353, by replacing the 4-methyl-2,
6-diaminopyrimidine moiety of the template with a benzyl
carbamate function (Fig. 1). This new compound was tested
against human DNMT1 and DNMT3A in vitro. Then, it
was tested in a stable cellular luciferase cytomegalovirus
(CMV) reporter system (CMV-luc) integrated in human
leukemia KG-1 cells in which the luciferase gene is under
the control of the methylated CMV promoter, as well as in
HCT116 human colon cancer cells to detect its ubiquitin
C-terminal hydrolase L1 (UCHL1) promoter demethylating
ability, revealed by enhanced green fluorescent protein
(EGFP) reporter gene expression. Moreover, MC3353 was
tested in a panel of cancer cells (HCT116 colon cancer,
KG-1, U-937 acute myeloid leukemia, MDA-MB-231 breast
cancer, RAJI Burkitt’s lymphoma, and PC-3 prostate cancer)
to determine its effects on cell proliferation, viability, and
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apoptosis/necrosis induction. SGI-1027, as well as
DAC and/or 5-AZA, were used as reference drugs in
all assays. In addition, the effect of MC3353 on
epithelial-to-mesenchymal transition (EMT), a process
controlling cellular invasiveness, was investigated in
PC-3 and HCT116 cells. The recent results provided
by MC3343 treatment of osteosarcoma cell and
mouse models [22] suggested us to also test MC3353
in this cellular context. Accordingly, we evaluated the
effect of MC3353 on the proliferation of patient-
derived Saos-2, U-2OS, MG63, IOR/OS9, IOR/OS20,
IOR/SARG, and patient-derived xenograft PDX-
OS#1-C4 cells. Finally, we tested the impact of
MC3353 on the expression of three genes [collagen
type I alpha 2 chain (COL1A2), alkaline phosphatase
(ALP), and osteocalcin (OCN)] involved in osteosar-
coma differentiation processes as well as on matrix
mineralization in Saos-2 cells.
Materials and methods
Chemistry
Melting points were determined on a Büchi 530 melting
point apparatus and are uncorrected. 1H nuclear mag-
netic resonance (NMR) and 13C NMR spectra were re-
corded at 400MHz on a Bruker AC 400 spectrometer;
chemical shifts are reported in δ (ppm) units relative to
the internal reference tetramethylsilane (Me4Si). EIMS
spectra were recorded with a Fisons Trio 1000 spec-
trometer; only molecular ions (M+) and base peaks are
given. All compounds were routinely checked by thin
layer chromatography (TLC), 1H NMR, and 13C NMR
spectra. TLC was performed on aluminum-backed silica
gel plates (Merck DC, Alufolien Kieselgel 60 F254) with
spots visualized by UV light. All solvents were reagent
grade and, when necessary, were purified and dried by
standard methods. The concentration of solutions
after reactions and extractions involved the use of a
Fig. 1 Chemical structures of known nucleoside and non-nucleoside DNMT inhibitors
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rotary evaporator operating at a reduced pressure of
ca. 20 Torr. Organic solutions were dried over anhyd-
rous sodium sulfate. Elemental analysis has been used
to determine the purity of the described compounds
that is > 95%. Analytical results are within ± 0.40% of
the theoretical values. All chemicals were purchased
from Sigma-Aldrich, Milan (Italy) or Alfa Aesar,
Karlsruhe (Germany) and were of the highest purity.
Benzyl (4-(4-(quinolin-4-ylamino) benzamido)
phenyl)carbamate (MC3353)
Triethylamine (0.37 mmol, 0.05 mL) and benzyl chloro-
formate (0.28 mmol, 0.04 mL) were slowly added to a
cooled (0 °C) solution of N-(4-aminophenyl)-4-(quinoli-
n-4-ylamino)benzamide 1 [20] (0.1 g, 0.28 mmol) in
tetrahydrofuran (5 mL), and the resulting mixture was
stirred at room temperature for 1.5 h. Then, the reaction
was quenched by water and extracted by dichlorometh-
ane (3 × 10mL), washed with brine (3 × 10 mL), then
dried with anhydrous sodium sulphate, filtered, and con-
centrated under reduced pressure. The oily residue was
purified by column chromatography (SiO2 eluting with
ethyl acetate/methanol 10/1) to provide pure MC3353.
Melting point: 220–222 °C; recrystallization solvent:
acetonitrile/methanol; yield: 72%; 1H NMR (DMSO-d6,
400MHz, δ; ppm) δ 5.16 (s, 2H, -CH2Ph), 7.20–7.49
(m, 10H, benzene protons), 7.58–7.60 (t, 1H, quinoline
proton), 7.67–7.76 (m, 3H, benzene protons and quin-
oline proton), 7.92–8.01 (m, 3H, benzene protons),
8.37–8.39 (d, 1H, quinoline proton), 8.57–8.59 (d, 1H,
quinoline proton), 9.24 (bs, 1H, -NH), 9.72 (bs, 1H,
-NHCOOBn), 10.09 (bs, 1H, -NHCOPh) ppm; 13C NMR
(DMSO-d6, 100MHz, δ; ppm) δ 66.8, 111.4 (2C), 112.8,
121.6, 121.8 (4C), 124.2 (2C), 125.7, 127.1 (2C), 127.6,
128.9 (2C), 129.2, 129.6, 130.2 (2C), 133.5, 133.6, 136.1,
138.7, 149.3, 149.7, 151.6, 153.8, 164.7 ppm; MS (EI), m/
z [M]+ C30H24N4O3 calculated 488.1848, found
488.1852. Elemental analysis: calculated %: C, 73.76; H
4.95; N 11.47. Found %: C, 73.88; H, 5.06; N, 11.20.
Dissolution of compounds
5-AZA (Sigma-Aldrich, Milan, Italy) was solubilized in a
HOAc:H2O (1:1) solution at 200 mM. All other com-
pounds including RG108 (synthetized as previously de-
scribed in [17]), SGI-1027 (synthetized as previously
described in [20]), DAC (Sigma-Aldrich, Milan, Italy),
and MC3353 were resuspended in DMSO (Sigma-Al-




His-DNMT1 (182 kDa, human) was cloned, expressed,
and purified as described by Lee et al. [15]. The
DNMT1 assay was performed according to Gros et al.
[25]. Briefly, the DNMT1 enzymatic assay is based on
the use of radiolabeled SAM, and the methylation oc-
curs in homogeneous phase in 384-well microplates.
The reaction is performed with DNMT1 at the final
concentration of 90 nM in a total volume of 10 μL
including also the chemical compound to be tested at
the desired concentration, 1.25 μM of SAM//
[methyl-3H] SAM (3TBq/mmol) mix in a ratio of 3:1
and 0.3 μM of biotinylated DNA duplex. DNMT1, as
“maintenance” methyltransferase, requires hemimethy-
lated DNA for the reaction. After 2 h incubation at
37 °C, 8 μL of the reaction’s solution is transferred
into a streptavidin 96-well scintillant coated Flashpla-
teTM containing 190 μL of 20 mM SAH in 50 mM
Tris-HCl (pH 7.4). The FlashplateTM is then agitated
at room temperature for 1 h and washed. The plate is
read with TopCount (PerkinElmer, Villebon-sur-Yvette,
France). The greater the DNMT1 inhibition, the lower
will be the scintillation signal correlated to the in-
corporation of the tritiated methyl groups. In this
assay, the negative and positive controls were defined
as wells without enzyme and wells without any com-
pound but just DMSO, respectively.
DNMT3A assay
DNMT3A enzyme inhibition was adapted from the
restriction-based fluorescence assay protocol described
in Ceccaldi et al. [18]. Briefly, it is performed in a
384-well microplate in a total volume of 50 μL. An oligo-
nucleotide labeled at the 5′ end with biotin is hybridized
to his complementary strand labeled at the 3′ end with
6-carboxyfluorescein. The DNA duplex thus formed
contains only one single CpG site overlapping with a re-
striction site of a methylation sensitive restriction enzyme.
The duplex is transferred in the wells coated with avidin.
Thus, the duplex is fixed to the plate. The methylation re-
action is performed by adding human C-terminal
DNMT3A at the final concentration of 4 ng/μL in a total
volume of 50 μL in the presence of the chemical com-
pound to be tested at the desired concentration and the
cofactor SAM at the final concentration of 20 μM. After
incubation (1 h at 37 °C), the plate is washed and the
methylation sensitive restriction enzyme HpyCH4IV is
added. After 1-h incubation at 37 °C, the plate is washed
and the fluorescence measured with a PerkinElmer
Envision Multilabel Plate Reader (PerkinElmer, Villebon-
sur-Yvette, France). The data are expressed as a percent-
age of inhibition vs. log concentration (M). Data are
normalized referring to the “restriction control” (wells
coated with labeled duplex not treated nor exposed to
DNMT3A, but only cleaved by HpyCH4IV) as the max-
imum of inhibition (100%) and to the “DMSO control”
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(wells coated with labeled duplex but treated just with
0.1% DMSO exposed to DNMT3A and then to
HpyCH4IV) as the minimum of inhibition (0%; total
methylation).
CMV-luc assay in KG-1 cells
The assay was carried out as described by Rilova et
al. [26]. The KG-1 cell line was stably transfected
with the luciferase firefly (Luc+ from pGL3 by Pro-
mega, Madison, WI, USA) reporter gene under the
control of a methylated CMV promoter (from
pEGFP-N1 by Clontech) and selected for the main-
tenance of the methylation of CMV and luciferase ex-
pression silencing (KG-1 CMV-luc). The stably
integrated KG-1 CMV-luc cells are cultivated in
RPMI-1640 medium (Lonza, Strasbourg, France),
supplemented with 10% FCS (Lonza, Strasbourg,
France) and 0.5 mg/mL of geneticin (Sigma-Aldrich,
Saint-Quentin Fallavier, France), under 5% CO2, at 37
°C and seeded at 20,000 cells per well in 96-well
plates. After 5 or 24 h of incubation in the presence
of compounds or the solvent DMSO, the induction of
the promoter is measured by quantification of lucifer-
ase with the Brite-lite assay system (PerkinElmer,
Villebon-sur-Yvette, France) according to the manu-
facturer’s protocol. The luminescence is measured on
an EnVision™ Multilabel Plate Reader (PerkinElmer,
Villebon-sur-Yvette, France), and the data are
expressed as fold induction compared to DMSO con-
trol. The mean of 2–4 experiments and its standard
error are reported.
To determine the antiproliferative activity of MC3353
in KG-1 cells, the cells were seeded at day 0 in a 96-well
plate and treated with test compound solutions at a dose
range spanning from 3.2 × 10−9 to 1 × 10−5 M at days 1,
2, and 3. On day 4, cell viability was assessed using the
ATPLite kit (PerkinElmer, Villebon-sur-Yvette, France).
UCHL1 promoter demethylation assay (luciferase activity
induction) in HCT116 colon cancer cells
Cell culture and treatments Human colon cancer
HCT116 (ATCC, VA, USA) cells were propagated in
McCoy’s 5A medium (Euroclone, Milan, Italy) with 10%
fetal bovine serum (FBS; Euroclone), 2 mM L-glutamine
(Euroclone), and antibiotics (100 U/mL penicillin, 100 g/
mL streptomycin) (Euroclone). For the treatments with
MC3353, 5-AZA, and DAC as positive controls, 2 × 104
cells were seeded in 6-well plates in triplicate. Cells were
treated every 2 days, and the medium was changed. On
day 5, cells were observed under a fluorescent micro-
scope. The nuclei were counterstained with DAPI
(10 μg/mL, Invitrogen, Tournai, Belgium).
Fluorescence detection Fluorescence of EGFP and
DAPI in living cells was analyzed by Cytation™ 5 Cell
Imaging Multi-Mode Reader (BioTeK, Milan, Italy).
Transfection Before the transfection, the pUMLIEP vec-
tor was linearized by with ClaI restriction enzyme (New
England Biolabs, Milan, Italy) and then it was methylated
by SssI-methylase (New England Biolabs, Milan, Italy) for
60min. The methylated vector was transfected into
HCT116 cells using Lipofectamine™2000 (Invitrogen,
Monza, Italy) and Opti-MEM® (Gibco, Monza, Italy), and
stably introduced clones were selected with puromycin
(1.0 μg/mL, Sigma-Aldrich, Milan, Italy). The detailed
protocol for the generation of cells highly responsive to
DNA demethylating agents is described in [27].
Cell lines and culture conditions
U-937 (acute myeloid leukemia), RAJI (Burkitt’s lymph-
oma), PC-3 (prostate cancer), and MDA-MB-231 (breast
cancer) cell lines were obtained from the Deutsche
Sammlung für Mikroorganismen and Zellkulturen
(DSZM, Braunschweig, Germany) and were cultured in
RPMI 1640 (Lonza, Verviers, Belgium) complemented
with 10% FBS (Lonza, Verviers, Belgium) and 1%
antibiotic-antimycotic (Lonza). RPMI1788 (normal B
lymphocytes) and KG-1 (acute myeloid leukemia) cell
lines were obtained from the American Type Culture
Collection (ATCC) and were maintained in RPMI 1640
complemented with 20% FBS and IMDM complemented
with 10% FBS, respectively. Cell lines were treated with
compounds at the indicated concentrations in the expo-
nential growth phase.
Peripheral blood mononuclear cells (PBMCs) from
healthy donors were isolated as previously described
[28]. Freshly isolated PBMCs were either cultured [28]
and treated at 1.106 cells/mL (non-proliferating PBMCs)
or stimulated with phytohaemoagglutinin (PHA) and
interleukin (IL)-2 (called PHA_PBMCs) to induce
blastogenesis in T lymphocytes before treatments as previ-
ously described [29]. Briefly, freshly isolated PBMCs were
seeded at a concentration of 2.106 cells/mL in RMPI 1640
supplemented with 1% antibiotic-antimycotic (Lonza,
Verviers, Belgium) and 10% human AB serum (Corning,
Fisher scientific, Merelbeke, Belgium). After overnight in-
cubation, floating lymphoid cells were collected and
seeded at 1.106 cells/mL in RMPI 1640 supplemented with
1% antibiotic-antimycotic, 5% FBS, 10% human AB serum,
1 μg/mL PHA (Gentaur, Kampenhout, Belgium), 50 U/mL
IL-2 (Roche, Prophac, Luxembourg City, Luxembourg),
1% non-essential amino acids (Invitrogen, Luxembourg),
1% HEPES (Invitrogen, Luxembourg), 1% sodium pyruvate
(Invitrogen, Luxembourg), and 0.1% β-mercaptoethanol
(Invitrogen, Luxembourg). After 72 h, the cells were seeded
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at 1.106 cells/mL in the same mitogenic growth medium
described just above and treated with test compounds.
The patient-derived human OS cell lines Saos-2,
U-2OS, and MG-63 were obtained from ATCC (1992).
The patient-derived OS cell lines IOR/OS9, IOR/OS20,
and IOR/SARG were established and previously charac-
terized at the Laboratory of Experimental Oncology of
Rizzoli Orthopedic Institute [30]. Cell lines were profiled
for DNA copy number changes [31] and DNA methyla-
tion status at approximately 27,000 CpG sites [32]. The
cell line PDX-OS#1-C4 was obtained from OS
patient-derived xenograft (PDX) after 4 passages in the
animal. All cell lines were tested for mycoplasma con-
tamination (Mycoalert Mycoplasma Detection Kit,
Lonza, Verviers, Belgium) before use and authenticated
by short-tandem repeat polymerase chain reaction (STR
PCR) analysis (last control December 2017) using
PowerPlex ESX fast System kit (Promega, Madison, WI,
USA). The following loci were verified: AMEL,
D3S1358, TH01, D21S11, D18S51, D10S1248, D1S1656,
D2S1338, D16S539, D22S1054, VWA, D8S1179, FGA,
D2S441, D12S391, D19S433, and SE33. All cell lines
were immediately amplified to constitute liquid nitro-
gen stocks and were never passaged for more than 1
month upon thawing. Cells were maintained in
Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 10% heat-inactivated FBS (Lonza, Verviers,
Belgium), penicillin (20 U/mL), and streptomycin (100 μg/
mL) (Sigma-Aldrich, Milan, Italy) in 37 °C humidified at
5% CO2.
Cell proliferation experiments
DKO HCT116 (ATCC, VA, USA) cells were propagated
in Dulbecco’s modified Eagle medium (DMEM) (Euro-
clone, Milan, Italy) with 10% fetal bovine serum (FBS;
Euroclone, Milan, Italy), 2 mM L-glutamine (Euroclone,
Milan, Italy) and antibiotics (100 U/mL penicillin, 100 g/
mL streptomycin) (Euroclone, Milan, Italy).
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] (Sigma-Aldrich, Milan, Italy) assay
was used to determine the proliferation of HCT116
clone and DKO HCT116 cells after treatment with
MC3353, 5-AZA, and DAC. 5 × 104 cells/well for both
cell lines were plated in 24-well plate and treated, in du-
plicate, with compounds at several concentrations for 24
and 48 h of induction. After treatments, MTT solution
was added for 3 h at 0.5 mg/mL, the purple formazan
crystals were dissolved in DMSO (Sigma-Aldrich, Milan,
Italy), and the absorbance was read at a wavelength of
570 nm with reader TECAN M-200.
Proliferation and viability of U-937, KG-1, RAJI, PC-3,
MDA-MB-231, RPMI1788, PBMCs, and PHA_PBMCs
were assessed by trypan blue exclusion assays at the
indicated time points. Nuclear morphology changes as-
sociated with apoptosis and necrosis were evaluated by
fluorescence microscopy after Hoechst and propidium
iodide (PI) staining as previously described [33].
To perform osteosarcoma cell growth inhibition exper-
iments, 2 × 105 cells/well were plated, and MC3353
(0.1–30 μM) or DAC (0.5 μM) was added after 24 h.
Cells were exposed for up to 96 h before being counted
by Trypan blue vital cell count (Sigma-Aldrich, Milan,
Italy). In parallel, the cells were treated with
DMSO-containing medium as a control. The highest
final concentration of DMSO in the medium was
< 0.005%, and DMSO had no effect on cell growth.
RNA extraction, reverse transcription, and quantitative
PCR in PC-3 and HCT116 cells for EMT pathway
evaluation
RNAs were extracted by ReliaPrep™ RNA Tissue
Miniprep (Promega, Madison, WI, USA) and reverse
transcribed with PrimeScript RT Master Mix (Takara,
Kusatsu, Shiga, Japan). cDNAs were amplified by a
qPCR reaction using GoTaq qPCR Master Mix
(Promega) and analyzed with the oligonucleotide pairs
specific for the target genes. Relative amounts, deter-
mined with the 2(−ΔCt) method, were normalized with re-
spect to the human housekeeping gene L32. The
primers used are as follows: L32 (forward: 5′-GGAG
CGACTGCTACGGAAG-3′, reverse: 5′-GATACTGTC
CAAAAGGCTGGAA-3′), E-cadherin (forward: 5′-TAC
GCCTGGGACTCCACCTA-3′, reverse: 5′-CCAGAA




Cells were lysed in Laemmli buffer; subsequently, the
proteins were resolved by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred to a
0.45-μm nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA). The following primary antibodies were
used for immunoblotting: α-E-cadherin (BD Transduc-
tion Laboratories, Franklin Lakes, NJ), α-MMP2
(Abcam), α-DNMT3a (Santa Cruz Biotechnologies, Dal-
las, TX), and α-GAPDH (Millipore Corp., Bedford, MA),
used as a loading control. The immune complexes were
detected with horseradish peroxidase-conjugated
species-specific secondary antiserum (Bio-Rad Labora-
tories, Milan, Italy) then by enhanced chemilumines-
cence reaction (Bio-Rad Laboratories, Milan, Italy).
Densitometric analysis of protein expression was per-
formed by using the Fiji ImageJ image processing
package.
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Osteosarcoma (Saos-2) differentiation towards osteoblasts
Four days after seeding, Saos-2 cells were exposed to
specific osteogenic medium (IMDM supplemented with
2% FBS, 5 mM β-glycerophosphate, and 50 μg/mL ascor-
bic acid, Sigma-Aldrich, Milan, Italy) without (control)
or with MC3353 (0.5–1 μM) or DAC (0.1–0.5 μM) and
maintained in differentiating conditions for up to 21
days. The medium was renewed every 4 days, and the
cells were harvested at various time points to collect
total RNA and verify bone mineralization. Specific osteo-
blastic markers were evaluated by quantitative real-time
PCR (RT-qPCR) as previously described [34]. The
primers or assays (Applied Biosystems, Foster City, CA,
USA) used are as follows: GAPDH (forward: 5′-GAAG
GTGAAGGTCGGAGTC-3′, reverse: 5′-GAAGATGGT
GATGGGATTTC-3′ and probe: 5′-CAAGCTTCC
CGTTCTCAGCC-3′), OCN (forward: 5′-GGGC
TCCCAGCCATTGAT-3′, reverse: 5′-CAAAGCCTT
TGTGTCCAAGCA-3′), ALP (Hs01029144_m1), and
COL1A2 (Hs01028970_m1). Amplification reactions
were performed using a ViiA7™ Real-Time PCR Sys-
tem (Life Technologies, Carlsbad, CA, USA). To
visualize bone mineralization (osteoblastic differenti-
ation) after 7–21 days of MC3353 or DAC treatment,
the plates were stained with 40 mM Alizarin red stain
(ARS, Sigma-Aldrich, Milan, Italy). ARS staining was
visualized with an ECLIPSE 90i microscope (Nikon,
Minato, Tokyo, Japan) equipped with Plan fluor 10×
NA 0.3. Images were acquired with an autocapture
setting using a digital color camera (Nikon DS5 MC)
and NIS-Elements AR3.10 software (Nikon, Minato,
Tokyo, Japan).
IC50 values determination and statistical analyses
IC50 values of compounds against cellular viability
were determined by using nonlinear regression fitting
curves with GraphPad Prism 8 or CalcuSyn software
The t test used for statistical analyses was performed
with GraphPad Prism 8. All the tests were one-tailed,




MC3353 was prepared by treating the known N-(4-ami-
nophenyl)-4-(quinolin-4-ylamino)benzamide 1 [20], dis-
solved in dry tetrahydrofuran, with benzyl chloroformate
in the presence of triethylamine (Scheme 1).
DNA methylation inhibiting assays
MC3353 was tested against human DNMT1 (hDNMT1)
and the C-terminal catalytic domain of human
DNMT3A (hDNMT3A) to assess its inhibitory activity.
RG-108 and SGI-1027 were used as reference drugs
(Table 1).
In enzyme assays, MC3353 showed increased potency
compared to RG-108 and lower efficacy with respect to
SGI-1027. In particular, it was 6-fold more potent than
RG-108 and 5.6-fold less effective than SGI-1027 against
hDNMT1, whereas against hDNMT3A, the potency dis-
played by MC3353 was > 29-fold higher than RG-108
and 20-fold lower than SGI-1027.
Afterwards, MC3353 was tested in KG-1 leukemia cells
for its ability to reactivate gene expression in a stably inte-
grated luciferase reporter construction under the control
of a CMV promoter inhibited by DNA methylation
(CMV-luc assay) [23, 26]. After 5 or 24 h of incubation in
the presence of drugs at the indicated concentrations, the
luciferase signal was measured and normalized to the
value of the non-treated cells (Table 2). Since the
CMV-luc assay is highly compromised when the tested
compounds induce cell death, the cytotoxicity of MC3353
Scheme 1 Synthesis of MC3353. Reagents and conditions: (a): (C2H5)3N, anhydrous THF, 0 °C, 1.5 h
Table 1 EC50 inhibition data of MC3353 against the enzymatic
activity of human DNMT1 and human DNMT3A through
radioactivity and fluorescent assay, respectively [18, 25]
Compound EC50 ± SD, μM
hDNMT1 hDNMT3A
MC3353 67 ± 4 17 ± 3
RG-108 390 ± 50 > 500
SGI-1027 12 ± 2 0.8 ± 0.2
EC50 are reported as the median concentration, at which a compound inhibits
50% of the DNA methylation and the standard deviation (SD) of at least two
independent experiments for DNMT1 and DNMT3A
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against KG-1 cells at 5 and 24 h was determined in paral-
lel. MC3353 was highly toxic for KG-1 cells after 24 h of
treatment starting from a concentration of 1 μM (Add-
itional file 1: Table S1 and indicated in stars in Table 2).
Nevertheless, 1 μM MC3353 strongly enhanced lucif-
erase expression after 5 h of treatment, while the induc-
tions observed at 1 μM after 24 h and at 5 μM after 5 h
are partially impaired by MC3353-induced cytotoxicity
(Table 2). Of note, MC3353 induced luciferase expres-
sion at a lower concentration compared to the reference
drug SGI-1027.
Next, the demethylating activity of MC3353 was evalu-
ated in cells transfected with luciferase and EGFP
reporter genes driven by the UCHL1 promoter [27]. The
UCHL1 promoter is silenced by methylation in human
colon cancer [35] and can be demethylated by specific
treatments, inducing expression of Metridia luciferase
and EGFP reporter genes. In particular, the pUCHL1
vector, after methylation, was transfected into HCT116
colon cancer cells, and the stable clone was obtained by
puromycin selection. Afterwards, cells were treated with
5-AZA (5 μM), with DAC (5 μM), or with MC3353
(0.1 μM) for 5 days. Such a low MC3353 dose was used
because of its cytotoxicity at higher concentrations in
long treatments. Microscopy and FACS analyses revealed
that in comparison with control cells (DMSO), MC3353
Table 2 Fold induction of the luciferase signal of the CMV-luc construct in MC3353 or SGI-1027 treated KG-1 cells
Compound Luciferase expression (fold ± SDa)
0.1 μM 1 μM 5 μM
5 h 24 h 5 h 24 h 5 h 24 h
MC3353 1.0 ± 0.05 1.1 ± 0.1 5.8 ± 0.9 4.4 ± 3.5* 6.7 ± 0.8* ND
SGI-1027 1.2 ± 0.3 0.9 ± 0.1 1.0 ± 0.1 1.5 ± 0.1 4.0 ± 1.2 9.8 ± 4.7*
ND not detected, SD standard deviation
*Partial toxic effect on KG-1 cells induced strong variations on promoter induction
aAll experiments were performed from n = 2 to n = 4
Fig. 2 EGFP expression. MC3353 strongly demethylates pUCHL1 in human HCT116 colon cancer cells. Microscopy imaging (a–d) and FACS
evaluation (e) of HCT116 cells transfected with a methylated pUCHL1 vector and treated for 5 days with DMSO as vehicle control (Ctr), 5-AZA,
DAC, and MC3353 at indicated concentrations. The drugs were added every 2 days, and the medium was changed
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strongly induced (81.4%) EGFP gene expression, witnes-
sing a specific DNA demethylating activity in cells. Inter-
estingly, MC3353 was markedly more effective than
both 5-AZA and DAC, which displayed an induction of
38.5% and 49.7%, respectively, at a 50-fold higher con-
centration (Fig. 2).
Next, we sought to evaluate whether, along with its
strong demethylating activity, MC3353 could impair
cancer cell proliferation and whether this effect was
DNMT-dependent. Accordingly, we tested the effect of
increasing concentrations of MC3353 on the prolifera-
tion of wild type as well as double DNMT knockout
(DKO) HCT116 colon carcinoma cells treated for 24
and 48 h [36]. Moreover, we compared the effect of
MC3353 to the reference DNMTi 5-AZA and DAC. The
results clearly demonstrate that MC3353 markedly
decreased HCT116 proliferation starting at 0.5 μM after
48 h of incubation, whereas a negligible effect was
observed after 5-AZA treatment. A modest prolifera-
tion inhibition was elicitated by DAC treatment, used
at a 20-fold higher concentration (10 μM) than
MC3353 (Fig. 3a). Interestingly, when tested against
DKO HCT116 cells, MC3353 was markedly less effi-
cient to impair cell proliferation at 0.5 μM after 48 h
of treatment; nevertheless, at higher concentrations,
increased cytotoxicity was observed. No evidence of
cytotoxicity was shown by DAC treatment even at the
highest dose, whereas a weak effect was triggered by
5-AZA (Fig. 3b).
Effect of MC3353 on a panel of different cancer and
healthy cell models
To further extend our findings, MC3353 was also tested
in a panel of cancer cell lines (KG-1 and U-937 acute
myeloid leukemia, MDA-MB-231breast cancer, RAJI
Burkitt’s lymphoma, and PC-3 prostate cancer) to assess
its effects on cell proliferation and viability. The effect of
MC3353 on proliferating normal B lymphocyte cell line
RPMI1788 as well as non-proliferating and proliferating
PBMCs from healthy donors was also determined to
Fig. 3 Effect of MC3353 on human HCT116 (a) and on human DKO HCT116 (b) colon cancer cell proliferation. Cells were treated with increasing
doses of MC3353, 5-AZA, or DAC. After 24 and 48 h, cell proliferation was evaluated through MTT assay. Data represent the mean (± SD) of three
independent experiments
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assess the differential toxicity. DAC (1 μM) has been
used as a reference drug in these assays. MC3353
showed a greater potency than SGI-1027 against all
tested cancer cell lines as well as healthy cell models.
Nonetheless, due to the overall more potent effect on
cancer cell viability compared to normal cell models,
MC3353 displayed a better differential toxicity compared
to the reference drug SGI-1027 (Fig. 4 and Table 3).
Due to the discrepancy between its high potency in
cellular assays (at low micromolar/submicromolar
level for the reactivation of genes silenced by pro-




Fig. 4 Effect of MC3353 on cell proliferation and viability. Cells were treated with increasing doses of MC3353 or 1 μM DAC. After 24, 48, and 72
h, cell proliferation and viability were evaluated using trypan blue exclusion staining. Data represent the mean (± SD) of three independent
experiments. a Cancer and b normal peripheral blood B lymphocyte (RPMI1788) cell line and c PBMCs from healthy donors
Table 3 Cell viability IC50 values for KG-1, U-937, RAJI, PC-3, MDA-MB-231, RPMI1788, and non-proliferating or proliferating PBM cells
after 48 h of treatment with MC3353 or SGI-1027
Compound IC50 ± SD
a, μM (Selectivity indexb)
KG-1 U-937 RAJI PC-3 MDA-MB-231 RPMI1788 PBMCs PHA_PBMCsc
MC3353 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.9 ± 0.4 0.9 ± 0.7 2.4 ± 0.2 8.9 ± 4.2 4.6 ± 0.5
(IC50 RPMI1788/IC50 cell line) (7.2) (6.6) (6.3) (2.7) (2.6) (NA) (NA) (NA)
(IC50 PBMCs/IC50 cell line) (26.2) (24.0) (23.1) (9.8) (9.7) (NA) (NA) (NA)
(IC50 PHA_PBMCs/IC50 cell line) (13.5) (12.4) (11.9) (5.1) (5.0) (NA) (NA) (NA)
SGI-1027 3.6 ± 0.6 1.7 ± 1.5 7.8 ± 0.7 5.0 ± 0.6 8.5 ± 7.2 6.7 ± 1.3 18.1 ± 6.8 ND
(IC50 RPMI1788/IC50 cell line) (1.9) (3.9) (0.9) (1.3) (0.8) (NA) (NA) (NA)
(IC50 PBMCs/IC50 cell line) (5) (10.6) (2.3) (3.6) (2.1) (NA) (NA) (NA)
SD standard deviation, NA not applicable, ND not determined
aData are the mean of at least three independent experiments
bDifferential toxicity was calculated as the ratio of the IC50 normal cells (either PBMCs or RMPI1788) to the IC50 neoplastic cells
cPHA_PBMCs: phytohemagglutinin-stimulated PBMCs
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viability in a panel of cancer cell lines) and its bio-
chemical DNMT inhibition (micromolar range),
MC3353 was screened against a panel of 46 kinases
(ExpresS Diversity Kinase Profile, Cerep), taking into
account its structural similarity (presence of amino-
quinoline, p-aminobenzoic, and benzene-1,4-diamine
fragments) with kinase inhibitors. However, 10 μM
MC3353 induced an inhibition greater than 50% only
against RAF1, SRC Proto-Oncogene, and Non-
Receptor Tyrosine Kinase (Src) and tropomyosin re-
ceptor kinase A (TRKA) kinase activities (60, 57, and
67%, respectively), being much less potent or inactive
against all the other tested enzymes (Additional file 1:
Table S2). These results could, at least partly, explain
the potent cytotoxic activity exerted by MC3353.
Moreover, prompted by the evidence that SGI-1027
induced a selective downregulation of DNMT1 with
minimal or no effects on DNMT3A in different can-
cer cell lines [19], and that the DNMTi MC3343 de-
creased the expression of all DNMTs in primary
osteosarcoma cells [22], we tested MC3353 and the
reference drug SGI-1027, in HCT116 and PC-3 cells
to evaluate the putative MC3353 ability to provide a
similar effect. We performed this assay only for
DNMT3A, as it was the isoform more sensible to the
enzymatic inhibition by MC3353. Hence, western
blotting reveals that DNMT3A protein downregula-
tion was observed in both cell lines (Fig. 5) and
already detectable in HCT116 cells at the same con-
centration (0.1 μM) at which MC3353 displayed
strong demethylation activity (Fig. 2). A higher dose
(1 μM) was requested for achieving this result in
PC-3 cells. A moderate effect on DNMT3A expres-
sion level was detectable upon treatment with
SGI-1027 in mainly HCT116.
Next, we evaluated the cell death modality (i.e.,
apoptosis vs. necrosis) triggered by treatments with
MC3353 in KG-1, U-937, and RAJI cancer cells as
well as normal RPMI1788 cells by analyzing the nu-
clear morphological changes under fluorescence mi-
croscopy following Hoechst and PI staining (Fig. 6).
In KG-1 and U-937 AML cells, MC3353 induced
mainly apoptosis with a considerable increase between
0.5 and 1 μM. Similarly, in RAJI cells, there was a
drastic increase in cell death rate between 0.5 and
1 μM, associated with a shift from apoptosis to necro-
sis (Fig. 6). Finally, in MC3353-treated RPMI1788
cells, we observed a mixed type of cell death induc-
tion, mainly necrosis, starting from a concentration of
5 μM.
MC3353 reversed EMT by affecting E-cadherin and MMP2
expression
The EMT process is recognized as an important step of
tumorigenesis. In ovarian cancer, it was shown that the
majority of gene-specific transforming growth factor
(TGF)-β-induced methylation changes occur in CpG
islands located in or near promoters. Pathway analysis of
the hypermethylated loci identified functional networks
strongly associated with EMT and cancer progression,
including cellular movement, cell cycle, organ morph-
ology, cellular development, and cell death and survival.
Altered methylation and corresponding expression of
specific genes during TGF-β-induced EMT include
E-cadherin and collagen 1A1. Moreover, TGF-β induces
DNMT1, DNMT3A, and DNMT3B expression and ac-
tivities, and treatment with the DNMTi SGI-110 pre-
vents TGF-β-induced EMT [37, 38].
Prompted by these findings, we investigated the ability
of MC3353 to modulate EMT pathway, using 5-AZA
and DAC as reference drugs. Hence, MC3353 was tested
in human PC-3 and HCT116 cells at 0.1 and 1 μM for
24 h (Fig. 7) while the treatment with 5-AZA and DAC
was performed every 2 days for 5 days at 0.1, 1, and
5 μM. The levels of mRNA transcripts of E-cadherin and
matrix metalloproteinase-2 (MMP2) were determined.
E-cadherin is involved in the maintenance of the epithe-
lial identity and in the control of tumor invasiveness,
whereas MMP2, through degradation of type IV colla-
gen, the most abundant component of the basement
membrane, controls an essential step for metastatic
Fig. 5 Western blot analysis of DNMT3A protein expression levels in HCT116 and PC-3 cells exposed for 24 h to the indicated concentrations of
MC3353 or SGI-1027. GAPDH was used as a loading control. Blots are representative of two independent experiments
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progression of most cancers as well as for induction of
angiogenesis [39].
The results clearly show that treatment with MC3353
induced E-cadherin mRNA expression transcripts at a
very low and non-cytotoxic concentration (0.1 μM) in
HCT116 colon cancer cells, whereas in PC-3 cells, this ef-
fect was observed only at 1 μM dose. On the other hand,
opposite results were found analyzing MMP2 expression,
Fig. 6 Nuclear morphology analysis in U-937, RAJI, KG-1, and RPMI1788 cells. Cells were treated with increasing doses of MC3353. Upper panels—after
72 h of treatment, the nuclear morphology was analyzed by fluorescence microscopy after Hoechst and PI staining. Pictures are representative of three
independent experiments. Lower panels—the results of cell counting are represented as the mean (± SD) of three independent experiments
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Fig. 7 Effects of MC3353 on E-cadherin and MMP2 mRNA expression levels in PC-3 and HCT116 cancer cells. Cells were treated with vehicle (DMSO or
AcOH) used as control (CTR), MC3353 for 24 h, or 5-AZA or DAC for 5 days. a, b E-cadherin and c, d MMP2 transcripts quantification via qPCR in PC-3 and
HCT116 cancer cells. Each histogram represents the mean of four independent experiments. Significance is represented as *p < 0.05 and as **p < 0.01
related to the control groups
Fig. 8 Effects of MC3353 on E-cadherin and MMP2 protein expression levels in PC-3 cancer cells. Cells were treated with vehicle (DMSO) used as
control (CTR) or MC3353 for 24 h. a E-cadherin and MMP2 protein detection by western blot. GAPDH was used as a loading control. Blots are
representative of three independent experiments. b Densitometric analysis of E-cadherin and MMP2 protein expression. Significance is
represented as *p < 0.05 related to the control groups. Data were obtained from three independent experiments and expressed as mean ± SEM
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which was strongly downregulated especially in PC-3 cells.
Notably, while 5-AZA and DAC are able to induce
E-cadherin expression in both cell lines (at higher doses in
PC-3 cells, from 1 to 5 μM), they are unable to downregu-
late MMP2 expression, indeed they increased MMP2 level
in both cell lines also at lower doses (0.1 to 1 μM).
In order to verify at the protein levels E-cadherin and
MMP2 regulation after MC3353 treatment, we analyzed
the protein expression in the PC-3 cells, in which the
changes are more relevant (Fig. 8).
The western blotting and its relative densitometric
analysis highlight that the treatment with MC3353 sig-
nificantly induced E-cadherin expression while reduced
MMP2 protein levels at 1 μM dose.
MC3353 impairs proliferation and modulates genes
expression and osteoblast differentiation in osteosarcoma
cells
The promising results observed in vitro and in vivo with
MC3343 treatments of osteosarcoma cells and mouse
model [22] encouraged us to investigate if its analog
MC3353 could prove anticancer properties in osteosar-
coma as well. Hence, the antiproliferative potential of
MC3353 was tested against patient-derived Saos-2,
U-2OS, MG63, IOR/OS9, IOR/OS20, IOR/SARG, and
PDX-OS#1-C4 cells. The results clearly highlight that,
similarly to the strong arrest of cell proliferation dis-
played in HCT116, KG-1, U-937, RAJI, PC-3, and
MDA-MB-231, was able to impair the osteosarcoma
cells growth with low single-digit micromolar IC50, being
comparable (Saos-2 and U-2OS) or more efficient (IOR/
OS9, IOR/OS20 and IOR/SARG cells) than DAC, used
as reference drug. Only in two osteosarcoma cell lines,
namely MG63 and PDX-OS#1-C4 MC3353, were ap-
proximately tenfold or threefold less potent than DAC
(Table 4). Next, we investigated the effects of the
DNMTi on the differentiation of Saos-2 cell line, which
displays osteoblast-like features and the ability to
differentiate toward the osteogenic lineage when
maintained in low-serum medium containing ascorbic
acid (50 μg/mL) and β-glycerophosphate (5 mM) [34].
Osteoblasts produce and secrete proteins that constitute
the bone matrix, such as collagens and osteocalcin, and
are essential for osteoid matrix mineralization, a process
mediated by alkaline phosphatase. Accordingly, we
evaluated the effects of MC3353 on the expression of
genes involved in the osteoblast differentiation such
as COL1A2, ALP, and OCN by RT-PCR (Fig. 9a), as
well as on the production of a mineralized matrix by
ARS staining (Fig. 9b). Thus, when tested at 0.5 and
1 μM and along 3 weeks, MC3353 dose-dependently
decreased COL1A2 expression, an early marker of
osteoblast differentiation, whereas it increased OCN
expression, a marker of terminal osteoblast differenti-
ation. The overall efficacy of MC3353 in the modula-
tion of the three genes was more evident at day 21.
Only at the most extended exposure, some weak in-
duction of ALP expression was detected. Moreover,
MC3353 proved to augment mineralized matrix pro-
duction, even better than 5-AZA, and this effect was
nicely observable after ARS staining (Fig. 9b).
Discussion
Aberrant DNA methylation of gene promoter regions
is presently recognized to be highly involved in hu-
man malignancies. Two nucleosides DNMTi, 5-AZA,
and DAC have been approved by the US FDA to treat
myelodysplasia; however, since they suffer from low
selectivity and water instability, combined to meta-
bolic liability, the discovery and identification of
non-nucleoside DNMTi and their validation in cancer
are highly pursued.
In 2014, we described the discovery of MC3343 as a
novel hit DNMTi showing higher potency and selectivity
than SGI-1027 with respect to other AdoMet-dependent
enzymes and a different mechanism of action. In cancer
cells, MC3343 showed similar antiproliferative potency
but less toxicity than SGI-1027. In medulloblastoma
cancer stem cells, MC3343 displayed arrest of prolifera-
tion and cytodifferentiation induction, and in osteosar-
coma cells, it affected tumor proliferation in vitro and in
vivo and provided osteoblastic differentiation by target-
ing and re-expressing specific genes.
Based on these findings, we designed a novel analog of
SGI-1027, MC3353, by replacing the 4-methyl-2,
6-diaminopyrimidine moiety with a benzyl carbamate
group. When tested against human DNMTs, MC3353
displayed micromolar inhibition of DNMT1 and
DNMT3A in enzymatic assays. To validate its ability to
demethylate DNA in cells, MC3353 was tested in
Table 4 IC50 values of cellular viability for osteosarcoma cell lines (Saos-2, U-2OS, MG63, IOR/OS9, IOR/OS20, IOR/SARG, PDX-OS#1-
C4) after 96 h of treatment with MC3353 or DAC
Compound IC50 ± SDa, μM
Saos-2 U-2OS MG63 IOR/OS9 IOR/OS20 IOR/SARG PDX-OS#1-C4
MC3353 1.1 ± 0.3 1.4 ± 0.1 2.4 ± 1.7 2.0 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 2.0 ± 0.1
DAC 1.0 ± 0.9 1.1 ± 0.9 0.2 ± 0.2 5.7 ± 3.4 9.2 ± 2.2 5.4 ± 1.0 0.7 ± 0.6
SD standard deviation
aData are the mean of at least two independent experiments
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leukemia KG-1 cells, where it was able to induce activa-
tion of the luciferase gene under the control of a methyl-
ated promoter in a CMV-luc reporter assay at 1 μM. In
parallel to this expression induction effect in leukemia
cells, in HCT116 cells, MC3353 was able to strongly in-
duce EGFP gene expression (81.4%), which is under the
UCHL1 promoter, silenced by methylation in colon can-
cer, hence underlining its specific demethylating activity
at a very low concentration (0.1 μM). In this assay,
MC3353 was markedly more effective than both 5-AZA
and DAC, which induced EGFP gene expression at 5 μM
of 38.5% and 49.7%, respectively, thus being the ap-
proved drugs less potent at a 50-fold higher
concentration.
Moreover, to correlate its demethylating activity to
antiproliferative effect, MC3353 was further tested in
HCT116 where it proved an efficient antiproliferative
agent already at 0.5 μM, being a lot stronger than
either 5-AZA or DAC. Noteworthy, when tested
against DKO HCT116 cells, MC3353 evidently dis-
played less potent antiproliferative effect at 0.5 μM, so
proving that the strong proliferation arrest shown at
this dose in HCT116 cells was, at least in part,
DNMT-dependent. However, augmented cytotoxicity
was highlighted in DKO HCT116 cells upon treat-
ment with MC3353 at higher doses, thus suggesting
some off-target engagement by MC3353. Next, our
DNMT inhibitor was screened against a panel of dif-
ferent cancer cell lines (KG-1, U-937, RAJI, PC-3, and
MDA-MB-231 cells), where it was more potent than
SGI-1027 and DAC in impairing cell viability (IC50
values in the low micromolar/submicromolar range).
Although MC3353 was also more toxic against nor-
mal proliferating and non-proliferating PBMCs and
RPMI1788 cells, due to its high potency, MC3353 dis-
played improved selectivity against cancer cell lines
compared to SGI-1027 in the tested models. The type
of cell death induced by MC3353 was mainly apop-
tosis in KG-1 and U-937 cells and necrosis in RAJI
and RPMI1788 lines. In U-937 cells, MC3353 initially
induced apoptosis and then necrosis at higher con-
centrations. Since MC3353 acts as a DNMTi at con-
centrations over 10 μM in the biochemical assay and
its potency in cancer cells is rather at low single-digit
micromolar or submicromolar level, we decided to in-
vestigate the additional mechanism(s) to explain this
uncorrelation. To address this issue, a screening against
46 kinases was performed, and MC3353 was found to in-
hibit over 50% RAF1, Src, and TRKA kinase activities at a
fixed dose of 10 μM. This additional target engagement
may contribute in part to the high cellular potency
highlighted by MC3353. Nevertheless, as already observed
in different cancer cell lines after SGI-1027 and MC3343
treatment, also the novel MC3353 provided protein deg-
radation of DNMT3A, the enzyme mainly inhibited. This
effect was revealed in both PC-3 and HCT116 cells, the
latter being the cell line where MC3353 displayed strong
demethylation activity and at the same dosage. This result
Fig. 9 Effects of MC3353 on osteoblastic differentiation in
osteosarcoma cells. a qRT-PCR expression of representative
osteoblast differentiation markers in Saos-2 osteosarcoma cells
treated with MC3353 at indicated concentrations under osteoblastic
conditions. COL1A2, ALP, and OCN are displayed to sign early,
intermediate, and late stages of the differentiation process,
respectively. The relative mRNA expression levels of target genes
(RQ) were calibrated on untreated cells (CTR) at each time point.
Data are the mean of at least two independent experiments; SD,
standard deviation. b ARS staining of a mineralized matrix over 7–
21 days of Saos-2 cells treatment with MC3353 or DAC at indicated
concentrations in differentiation medium. Scale bar indicates 200 μm
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also well correlates with the potent effect observed in all
the cell proliferation assays; indeed, DNMT3A degrad-
ation could give a contribution to the MC3353 efficacy in
all cellular experiments here studied. In addition, in PC-3
and HCT116 cells, this compound reversed the EMT
process by inducing E-cadherin (mainly in HCT116) and
reducing MMP2 (mainly in PC-3) mRNA transcripts
levels at low and non-cytotoxic concentrations (0.1 μM)
and after 24 h of treatment. With respect to MMP2, we
found that both 5-AZA and DAC, able to markedly in-
duce E-cadherin expression particularly at higher doses,
result unable to downregulate its expression, in accord-
ance with previous studies [40–42]. Interestingly, both
SGI-1027 and MC3353 were found to induce the down-
regulation of DNMT3A protein expression, indicating
their role not only on DNMT activity but also on protein
levels.
Next, MC3353 was also tested against several primary
osteosarcoma cell lines, where previously, its analog
MC3343 displayed inhibition of tumor proliferation and
induction of osteoblastic differentiation through the spe-
cific re-expression of related genes. MC3353 induced
COL1A2 downregulation together with ALP and mainly
OCN upregulation after 3 weeks of treatment mainly at
1 μM. Moreover, this compound increased also mineral-
ized matrix production after 3 weeks of treatment, as evi-
dence of the effect on differentiation from osteosarcoma
to osteoblast cells, even more efficiently than DAC, used
as a reference.
Conclusions
In conclusion, the present study reveals that the novel
DNMTi MC3353 displayed a stronger demethylating ac-
tivity than both 5-AZA and DAC in cell models through
both enzyme inhibition and protein downregulation, and
it was able to re-activate a methylation-silenced gene
such as UCHL1 in HCT116. Its dose- and time-
dependent antiproliferative activity was accompanied by
induction of cell death, differentiation, and genes modu-
lation, but also by impairment of the EMT process, as
shown by its E-cadherin and MMP2 modulating effect.
To the best of our knowledge, MC3353 is the first
non-nucleoside DNMTi with an effect on EMT pathway,
opening a novel scenario for biological investigation on
migration/invasiveness.
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